Picture of TMS Co logo

4891 TMS Co Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-18.61%
3m-22.38%
6m-27.7%
1yr-41.07%
Volume Change (%)
10d/3m-66.19%
Price vs... (%)
52w High-50.68%
50d MA-9.61%
200d MA-24.1%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-32.81%
Return on Equity-31.24%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
28th Feb 202528th Feb 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of TMS Co EPS forecast chart

Profile Summary

TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.

Directors

    Last Annual
    February 29th, 2024
    Last Interim
    May 31st, 2024
    Incorporated
    February 17th, 2005
    Public Since
    November 22nd, 2022
    No. of Shareholders
    9,172
    No. of Employees
    14
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    jp flag iconTokyo Stock Exchange
    Shares in Issue
    40,328,857

    4891 Share Price Performance

    Upcoming Events for 4891

    Q2 2025 TMS Co Ltd Earnings Release

    Dividend For 4891.T - 0.0000 JPY

    Similar to 4891

    Picture of 3-D Matrix logo

    3-D Matrix

    jp flag iconTokyo Stock Exchange

    Picture of AnGes logo

    AnGes

    jp flag iconTokyo Stock Exchange

    Picture of BrightPath Biotherapeutics Co logo

    BrightPath Biotherapeutics Co

    jp flag iconTokyo Stock Exchange

    Picture of Carna Biosciences logo

    Carna Biosciences

    jp flag iconTokyo Stock Exchange

    Picture of Chiome Bioscience logo

    Chiome Bioscience

    jp flag iconTokyo Stock Exchange

    FAQ